New drug duo shows promise against tough head and neck cancer

This study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively in people with advanced head and neck cancer. About 106 adults aged 18-75 with locally advanced squamous cell carcinoma of the head and neck will take part. Half will get MRG003 alone, and half will get MRG003 plus pucotenlimab, followed by chemoradiation and then additional pucotenlimab. The main goal is to see which group has a better tumor response.